https://www.selleckchem.com/pr....oducts/nutlin-3a.htm
formation on the risk of no-reflow and mortality in STEMI patients. There is considerable heterogenicity in clinical outcomes in Duchenne muscular dystrophy (DMD). The aim of this study was to assess whether dystrophin gene (DMD) pathogenic variant location influences upper or lower extremity motor function outcomes in a large prospective cohort. We used longitudinal timed and quantitative motor function measurements obtained from 154 boys with DMD over a 10-y period by the Cooperative International Neuromuscular Research Group Duchen
Beğen
Yorum Yap
Paylaş
